Date	Time		Session	Speakers	Moderators
Monday June 17	09:00-11:45		Registration		
	11:45-12:45		Lunch		
	12:45-13:15		Welcoming words	Leonard van den Berg and Caroline Ingre	
	13:15-14:30		**Session 1 - Population and disease registries and Epidemiology**	Fang Fang	Adriano Chio and Fang Fang
		1	Survival of ALS patients has increased over time: results from a long-standing register.	Rosario Bvasta	
		2	Increased incidence of motor neuron disease in Sweden: a population-based study during 2002-2021	Sofia Imrell	
		3	Epidemiology of Amyotrophic Lateral Sclerosis in Catalonia (Spain): 2015-2020	Sergio Vidal Notari	
		4	Amyotrophic lateral sclerosis caused by the C9orf72 expansion in Norway – prevalence, ancestry, clinical and demographic variables	Helle Høyer	
		5	A population-based disease mapping of ALS incidence in the Republic of Ireland from 1995 to 2022	Éanna Mac Domhnaill	
	14:30-15.00		Break		
	15:00-16:15		**Session 2 - Clinical**	Julian Grosskreutz and Philip van Damme	Caroline Ingre and Thomas Meyer
		6	Single-cell transcriptomics reveal the presence of clonally expanding T cells in ALS	ZhenZhen Chen	
		7	Glymphatic dysfunction occurs across clinical phenotypes of motor neuron disease	Edoardo Gioele Spinelli	
		8	Brain metabolic features of FUS-ALS: a 2-[18F]FDG-PET study	Antonio Canosa	
		9	Sex Differences in Amyotrophic Lateral Sclerosis Survival and Progression: A Multidimensional Analysis	Maurizio Grassano	
		10	Neurofilament content of patient sensory skin axons reflects ALS progression	Janina von der Gablentz	
		11	Understanding How Cognitive and Behavioural Impairments Affect the Mental Capacity to Make Treatment Decisions in ALS.	Milena Contreras	
	16:15-16:45		Break		
	16:45-17:30		**Rapid Fire Presentations A - Clinical**		Magdalena Kuzma
		I	FDG-PET clustering analysis in Amyotrophic Lateral Sclerosis.	Joke de Vocht	
		II	Targeting the energy deficit in ALS - the LIPCAL-ALS II study	Johannes Dorst	
		III	Rare variants in the genetic background modulate risk and phenotype in ALS	Maurizio Grassano	
		IV	Cognitive Deficits in ALS patients with SOD1 mutations	Ivar Winroth	
		V	Physical activity, fitness and long-term risk of amyotrophic lateral sclerosis - a prospective cohort study	Anders Myhre Vaage	
		VI	Exploring the Genetic Underpinnings of Cognition in ALS through Multi-Trait GWAS Analysis	Emrah Kacar	
		VII	Longitudinal cognitive assessment using the Cumulus home-based EEG platform in ALS and FTD.	Emmet Costello	
		VIII	Defining functional brain network changes in ALS at higher temporal resolution	Alicia Northall	
		IX	Associations between resting-state electroencephalographic (EEG) measures and cognitive functions in ALS: a preliminary region-specific analysis	Serena Plaitano	
		X	Association study on HERV-K genomic insertions in Amyotrophic Lateral Sclerosis	Simon Topp	
		XI	Is a brief apathy assessment useful in motor neuron disease clinics?	Ratko Radakovic	
		XII	Investigating the potential of apathy as a predictor for ALS trial-participation.	Juliette Foucher	
		XIII	Education mediates the association between motor and cognitive-behavioural features in non-demented ALS patients	Edoardo Nicolò Aiello	
		XIV	An update on the role of autoantibodies against neurofilaments in amyotrophic lateral sclerosis (ALS)	Ellie Sturmey	
		XV	BRAINTEASER Project: Enhancing Amyotrophic Lateral Sclerosis Care through Remote Monitoring and Artificial Intelligence Integration	Inês Alves	
	17:30-18:30		**Poster Session A**		
Tuesday June 18	08:30-9:45		**Session 3 - Pre-symptomatic changes and Imaging**	Joke de Vocht	Dorothee Lule and Sharon Abrahams
		12	A comparison of frameworks for identifying cognitive and behavioural impairment in pre-symptomatic ALS	Caroline McHutchison	
		13	ECAS correlation with metabolic alterations on FDG-PET imaging in ALS patients	Linn Öijerstedt	
		14	QSM-detected iron accumulation in the cerebellar gray matter selectively predicts executive dysfunction in non-demented ALS patients	Claudia Morelli	
		15	Cognitive endophenotypes and C9orf72 in familial ALS: a longitudinal study	Colm Peelo	
	09:45-10:15		Break		
	10:15-11:15		**Session 4 - Genetics**	Peter Andersen	Jan Veldink and Philippe Corcia
		16	Multiomic analysis to identify the genetic basis of amyotrophic lateral sclerosis	Calum Harvey	
		17	Plasma extracellular vesicle Tau and TDP-43 as diagnostic biomarkers in FTD and ALS	Anja Schneider	
		18	Using Irish Clan Genomics to Interrogate the Biological Overlap between Amyotrophic Lateral Sclerosis and Neuropsychiatric Disorders	Ciara O'Donoghue	
		19	Genome-wide screen for genetic modifiers in ALS progression	Ramona Zwamborn	
		20	The shared ancestry between the C9orf72 hexanucleotide repeat expansion and intermediate-length alleles using haplotype sharing trees and HAPTK	Osma Rautila	
	11:15-11:45		Break		
	11:45-12:30		**Debate: "ALS future: Targeted vs. Untargeted/Cocktail treatments?**	Angela Genge vs. Pamela Shaw	Leonard van den Berg
	12:30-14:00		Lunch		

	14:00-15:15		**Session 5 - Clinical trials and biomarkers**	Christopher McDermott	Martin Turner and Orla Hardiman
		21	Identification of proteomic clusters in the CSF of sporadic ALS patients	Laura Tzeplaeff	
		22	Combined rescue of STMN2 and UNC13A mis-splicing in ALS using a novel therapeutic approach	Puja Mehta	
		23	Serum neurofilament light chain in distinct phenotypes of amyotrophic lateral sclerosis – a longitudinal multicenter study	Thomas Meyer	
		24	Using ALS patient-derived astrocytes to identify patient stratification biomarkers in response to a promising multi-target drug	Raquel Rua Martins	
		25	Skin innervation across ALS clinical stages: new biomarkers of disease progression and survival	Raffaele Dubbioso	
		26	Longitudinal analysis of T cells responses in amyotrophic lateral sclerosis	Solmaz Yazdani	
	15:15-15:45		Break		
	15:45-17:00		**Platform presentation on trials: Phoenix, ADORE and Humanitas Research Hospital (TUDCA trial)**	Leonard van den Berg, Sabrina Paganoni and	Ammar Al-Chalabi and Orla Hardiman
	17:00-17:45		**Panel Discussion - About the New Standard of Care**	Leonard van den Berg, Jeremy Shefner, Ange	Ammar Al-Chalabi and Orla Hardiman
	17:45-18:45		**Poster Session B**		
	19:45-24:00		**Gala Dinner**		
Wednesday June 19	09:00-10:15		**Session 6 - Biomarkers; Basic and translational**	Leonard Petrucelli	Philipe van Damme and Sebastian Levandowski
		27	Stress granules and oxidation drive TDP-43 demixing in the cytoplasm	Jik Nijssen	
		28	Differential pathways of astrocyte toxicity in sporadic ALS	Katie Bowden	
		29	Investigating the metabolic crosstalk between senescent lymphocytes and microglia from patients with ALS	Victoria Tsang	
		30	toxic gain-of-function mechanisms, but not C9orf72 haploinsufficiency impairs the autophagy pathway in C9orf72 ALS/FTD iPSC-derived motor neurons.	Jimmy Beckers	
		31	Targeting EGLN2/PHD1 protects motor neurons and normalizes the astrocytic interferon response.	Christine Germeys	
		32	Exploring Metabolic Pathways in ALS: TDP-43, Mitochondria, and Ferroptosis Interplay	Miriam Ceron Codorniu	
	10:15-10:45		**Rapid Fire presentations B - Basic**		Monica Povedano
		XVI	Tbk1 mutant zebrafish show increased programmed cell death and dysregulation of critical pathways involved in Amyotrophic Lateral Sclerosis (ALS)	Quentin Raas	
		XVII	Characterising activity-related phenotypes in C9ORF72 iPSC MNs using optogenetics	Jiali Gao	
		XVIII	Impact of trauma on presymptomatic C9orf72 carriers and symptomatic patients using hiPSC-derived organoids as a double-hit model of neurodegeneration	Karthik Baskar	
		XIX	NEK1 regulates ER-mitochondria contacts.	Natalie Pye	
		XX	Comprehensive DNA methylation analysis shows no age acceleration in amyotrophic lateral sclerosis.	Polina Merbaum	
		XXI	Dysregulation of muscle cholesterol homeostasis in amyotrophic lateral sclerosis	Flore Cheguillaume	
		XXII	Disruption of the Angiopoietin-like protein system associates lipid homeostasis with hypothalamic dysfunction in ALS	Sruthi Sankari Krishnamurthy	
		XXIII	Altered Expression of Membrane Proteins in C9orf72 Mutation-Associated ALS and FTD	Urša Čerček	
		XXIV	Endothelial TDP-43 controls sprouting angiogenesis and vascular barrier integrity, and its deletion triggers neuroinflammation	Eloi Montañez	
		XXV	Activation of polo-like kinase 1 expression in spinal motor neurons underlies the increased vulnerability of spinal motor neurons in FUS-ALS	Andreas Hermann	
	10:45-11:15		Break		
	11:15-11:30		EU ALS Coalition	Julian Grosskreutz	Andrea Calvo
	11:30-11:50		Biogen Update	John Ravits	Andrea Calvo
	11:50-12:10		Himalaya trial	Nazem Atassi	Andrea Calvo
	12:10-12:20		**Börje Salming Award for best Rapid Fire Presentation**	Ulf Hedin	Caroline Ingre
	12:20-13:30		Lunch and posters		
	13:30-14:45		**Session 7 - Cellular, Molecular Biology and Animal Model**	Don Cleaveland	Eva Hedlund and Jeroen Pasterkamp
		33	(GR)400 and (PR)400 knock-in mice show a conserved neuroprotective role of an extracellular matrix signature in C9ALS/FTD	Carmelo Milioto	
		34	C-myc dysregulation contributes to glia-to-neuron miscommunication in Amyotrophic Lateral Sclerosis and Frontotemporal dementia	Manuela Basso	
		35	A TBK1 variant causes autophagolysosomal and motoneuron pathology without neuroinflammation in mice	David Brenner	
		36	Organellomics: AI-driven deep organellar phenotyping of human neurons	Lena Molitor	
		37	Modelling ALS caused by KIF5A mutations in patient-derived motor neurons	Isabel Loss	
		38	The homeoprotein transcription factor ENGRAILED-1 allows for spinal α-Motoneurons protection and repair	Alain Prochiantz	
	14:45-15:15		**Young Investigator and Poster Award**		Ammar Al-Chalabi and Caroline Ingre
	15:15-15:30		**Wrap-up and announce ENCALS 2025**	Leonard van den Berg, Caroline Ingre and Adriano Chio	